Survival Analysis of Our Patients Diagnosed with Testicular Cancer

Amaç & Hipotez:Objectives: The aim of our study is to determine the relationship between clinicopathological parameters and survival in our patients with testicular cancer who were followed up and treated in our centers.

📊

Temel Bulgular & Veri:Results: 164 patients with a mean age of 32.8±10.8 (range 15.6-67) years were included in the study.

💡

Sonuç & Katkı:A statistically significant difference was found between histological type and age (p

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: The aim of our study is to determine the relationship between clinicopathological parameters and survival in our patients with testicular cancer who were followed up and treated in our centers. Methods: Patients who were followed up and treated with the diagnosis of testicular cancer in Antalya Training and Research Hospital and Sanko University Hospital Medical Oncology Clinics were evaluated retrospectively. Results: 164 patients with a mean age of 32.8±10.8 (range 15.6-67) years were included in the study. Seminoma was detected in 68 (41.5%) patients, non-seminomatous germ cell tumor (NSGCT) was detected in 91 (55.5%) patients, and non-germ cell testicular carcinoma was detected in 5 (3%) patients. A statistically significant difference was found between histological type and age (p

🔖

Bu Makaleye Atıf Yap

YILDIRIM, M., SEVER, Ö. N., ENKİ, S., YILDIZ, M., YERLİKAYA, T., SOLAKHAN, M. (2022). Survival Analysis of Our Patients Diagnosed with Testicular Cancer. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 2, 176–179. https://ajindex.com/articles/508521

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33
American Cancer Society: Testicular cancer survival rates. Available at: https://www.cancer.org/cancer/testicularcancer/ detection-diagnosis-staging/survival-rates.html. Accessed Jan 19, 2022
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49
Znaor A, Skakkebaek NE, Rajpert-De Meyts E, Laversanne M, Kuliš T, Gurney J, et al. Testicular cancer incidence predictions in Europe 2010-2035: A rising burden despite population ageing. Int J Cancer 2020;147:820–8
T.C. Sağlık Bakanlığı. Türkiye kanser istatistikleri. Available at: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/ Turkiye_Kanser_Istatistikleri_2017.pdf. Accessed Jan 29, 2022
Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson AM, Eisenberg ML, et al. Male reproductive disorders and fertility trends: ınfluences of environment and genetic susceptibility. Physiol Rev 2016;96:55–97
Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C. Testicular germ cell tumours. Lancet 2016;387:1762– 74
Del Risco Kollerud R, Ruud E, Haugnes HS, Cannon-Albright LA, Thoresen M, Nafstad P, et al. Family history of cancer and risk of paediatric and young adult's testicular cancer: A Norwegian cohort study. Br J Cancer 2019;120:1007–14
Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fosså SD. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). Int J Cancer 2011;129:2867–74
Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al; ESMO Guidelines Committee, EURACAN. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow- up. Ann Oncol 2022:S0923-7534(22)00007-2.